Is there a benefit for CYP2C19 genotype-guided antiplatelet treatment in elderly acute coronary syndrome patients?
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Pharmacogenomics - 22(2021), 12 vom: 12. Aug., Seite 727-730 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
van den Broek, Wout Wa [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 10.02.2022 Date Revised 10.02.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/pgs-2021-0078 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327971037 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327971037 | ||
| 003 | DE-627 | ||
| 005 | 20231225201950.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/pgs-2021-0078 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM327971037 | ||
| 035 | |a (NLM)34251288 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a van den Broek, Wout Wa |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Is there a benefit for CYP2C19 genotype-guided antiplatelet treatment in elderly acute coronary syndrome patients? |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.02.2022 | ||
| 500 | |a Date Revised 10.02.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a CYP2C19 | |
| 650 | 4 | |a P2Y12-inhibitor | |
| 650 | 4 | |a acute coronary syndrome | |
| 650 | 4 | |a dual antiplatelet therapy | |
| 650 | 4 | |a elderly | |
| 650 | 4 | |a pharmacogenetics | |
| 650 | 7 | |a Platelet Aggregation Inhibitors |2 NLM | |
| 650 | 7 | |a Purinergic P2Y Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Clopidogrel |2 NLM | |
| 650 | 7 | |a A74586SNO7 |2 NLM | |
| 650 | 7 | |a CYP2C19 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 650 | 7 | |a Cytochrome P-450 CYP2C19 |2 NLM | |
| 650 | 7 | |a EC 1.14.14.1 |2 NLM | |
| 700 | 1 | |a Ten Berg, Jurriën M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmacogenomics |d 2000 |g 22(2021), 12 vom: 12. Aug., Seite 727-730 |w (DE-627)NLM111671396 |x 1744-8042 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:12 |g day:12 |g month:08 |g pages:727-730 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/pgs-2021-0078 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2021 |e 12 |b 12 |c 08 |h 727-730 | ||